Illumina (NASDAQ:ILMN) Reaches New 12-Month High – Here’s Why

Illumina, Inc. (NASDAQ:ILMN) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $156.09 and last traded at $157.0050, with a volume of 250999 shares traded. The stock had previously closed at $150.17.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent research reports. Evercore reissued an “outperform” rating on shares of Illumina in a report on Friday, May 1st. Robert W. Baird set a $137.00 target price on shares of Illumina in a report on Friday, February 6th. Weiss Ratings cut shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, UBS Group reissued a “neutral” rating and issued a $135.00 target price on shares of Illumina in a report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $137.75.

Illumina Stock Up 4.3%

The firm’s 50 day simple moving average is $132.17 and its 200 day simple moving average is $131.55. The company has a market cap of $23.70 billion, a price-to-earnings ratio of 28.50, a price-to-earnings-growth ratio of 2.40 and a beta of 1.42. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the business earned $0.97 earnings per share. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Christensen Jakob Wedel sold 700 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the transaction, the senior vice president owned 15,056 shares in the company, valued at $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 225,067 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the transaction, the director owned 3,604,441 shares in the company, valued at $524,626,387.55. This represents a 5.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 330,160 shares of company stock worth $48,028,308 in the last quarter. Company insiders own 2.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Capital World Investors increased its stake in shares of Illumina by 0.6% during the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after acquiring an additional 124,323 shares during the period. State Street Corp increased its stake in shares of Illumina by 3.2% during the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after acquiring an additional 190,324 shares during the period. WCM Investment Management LLC increased its stake in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after acquiring an additional 1,851,848 shares during the period. AQR Capital Management LLC increased its stake in shares of Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock valued at $580,531,000 after acquiring an additional 1,028,099 shares during the period. Finally, Geode Capital Management LLC grew its position in Illumina by 4.8% in the fourth quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after buying an additional 130,139 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.